Article Text

Download PDFPDF
Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis
  1. Salvatore D'Angelo1,
  2. Maria Stefania Cutro1,
  3. Ennio Lubrano2,
  4. Pietro Leccese1,
  5. Gianna Angela Mennillo1,
  6. Nicola Ferrara2,3,
  7. Ignazio Olivieri1
  1. 1Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy
  2. 2Fondazione Maugeri, IRCCS, Telese Terme, Italy
  3. 3Department of Health Sciences, School of Medicine, University of Molise, Campobasso, Italy
  1. Correspondence to Dr Ignazio Olivieri, Rheumatology Department of Lucania, Ospedale San Carlo, Contrada Macchia Romana, 85100 Potenza, Italy; ignazioolivieri{at}

Statistics from

Psoriatic arthritis (PsA) is a heterogeneous disease involving the musculoskeletal structures, the skin and nails.1 2 Traditional disease-modifying antirheumatic drugs and tumour necrosis factor β (TNFβ) antagonists are effective on cutaneous and articular manifestations of psoriatic disease.3 4

Most patients with PsA are successfully treated with TNFβ antagonists. However, a subset of patients with PsA are not responsive to these treatments or do not maintain a clinical response to the cutaneous manifestations despite the remission of arthritis.5

The primary objective of this study was to evaluate the safety and efficacy of adding ciclosporin A (CsA) to etanercept in patients with PsA demonstrating an unsatisfactory control of cutaneous …

View Full Text


  • Ethics approval This study was conducted with the approval of the Ospedale San Carlo.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.